Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..

The Role Of Immunotherapy In Lymphoma Treatment

If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..

CAR - T Cell therapy, CAR T Therapy, CAR T-Cell, chimeric agent

A Deep Dive into CAR T Cell Therapy: How Does It Work?

Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how ..

CAR T-Cell, CAR therapy, Immunotherapy, T cell therapy

Is CAR T-Cell Therapy Available In India?

Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..

B-cell lymphoma, DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Inde..

Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..

ASTCT, CIBMTR, Large B-cell lymphoma, Matthew Frank, Miltenyi Biotec, Stanford University

Novel treatment target for lymphoma patients who relapse after CAR-T therapy

Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..

Eli Lilly and Company, FDA, Food and Drug Administration, Jaypirca, Mantle cell lymphoma, MCL, pirtobrutinib

Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma

Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..

BeiGene USA, BRUKINSA, chronic lymphocytic leukemia, SEQUOIA, small lymphocytic lymphoma

Zanubrutinib is approved by FDA for chronic lymphocytic leukemia or small lymphocytic lymphoma

Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..

Adcetris, brentuximab vedotin, classical Hodgkin lymphoma, Seagen Inc

Brentuximab vedotin is approved by FDA in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

November 2022: The combination of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide with brentuximab vedotin (Adcetris, Seagen, Inc.) has been approved by the Food and Drug Administration for use in children an..